Souders Financial Advisors Purchases 483 Shares of Pfizer Inc. (NYSE:PFE)

Souders Financial Advisors grew its position in Pfizer Inc. (NYSE:PFE) by 6.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 8,347 shares of the biopharmaceutical company’s stock after buying an additional 483 shares during the period. Souders Financial Advisors’ holdings in Pfizer were worth $234,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Dana Investment Advisors Inc. boosted its position in shares of Pfizer by 9.6% in the 2nd quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock worth $2,803,000 after purchasing an additional 8,771 shares during the last quarter. Founders Financial Alliance LLC increased its holdings in shares of Pfizer by 3.6% in the second quarter. Founders Financial Alliance LLC now owns 28,419 shares of the biopharmaceutical company’s stock worth $795,000 after acquiring an additional 995 shares in the last quarter. 3Chopt Investment Partners LLC raised its position in shares of Pfizer by 97.9% during the second quarter. 3Chopt Investment Partners LLC now owns 22,767 shares of the biopharmaceutical company’s stock worth $637,000 after purchasing an additional 11,265 shares during the period. Heartland Bank & Trust Co acquired a new stake in shares of Pfizer during the second quarter worth about $596,000. Finally, IMS Capital Management grew its position in shares of Pfizer by 2.0% in the 2nd quarter. IMS Capital Management now owns 104,938 shares of the biopharmaceutical company’s stock valued at $3,033,000 after purchasing an additional 2,029 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, September 16th. UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Nine equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

Shares of PFE opened at $28.67 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company’s fifty day simple moving average is $29.28 and its 200 day simple moving average is $28.31. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11. The company has a market cap of $162.46 billion, a price-to-earnings ratio of -477.83, a PEG ratio of 1.27 and a beta of 0.68.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the business earned $0.67 EPS. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.